CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 enrolled
Drug / intervention
E7080drug
Likely dose
E7080 24 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01268293
NCT01268293Phase 1Completed
CompareCT.gov

A Phase 1 Study of E7080 in Subjects With Solid Tumor

Eisai Co., Ltd.·interventional·Posted Dec 30, 2010·Updated Jun 22, 2023

In Brief

A Phase 1 clinical trial evaluating E7080 for Cancer. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle) in subjects with solid tumors

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 30, 2010
Enrollment StartFeb 1, 2011
Primary CompletionDec 1, 2011
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.5 years ago

Interventions

E7080drug

This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.